anti-tumor
- تیر- 1397 -18 تیر
ASCO: Zymeworks posts early responses to bispecific antibody in HER2+ cancers
ASCO: Zymeworks posts early responses to bispecific antibody in HER2+ cancers Zymeworks unveiled new phase 1 clinical data from its lead bispecific antibody, ZW25, demonstrating…
-- بیشتر بخوانید -- - 6 تیر
This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer
This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer After failing its lead program and reshuffling its management, Innate Pharma has Phase I results…
-- بیشتر بخوانید --
